WA
MRKR icon

WealthTrust Axiom’s Marker Therapeutics MRKR Stock Holding History

WealthTrust Axiom’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,270
Closed -$6.04K – 258
2022
Q4 		$6.04K Hold
2,270
– – ﹤0.01% 244
2022
Q3 		$8K Hold
2,270
– – ﹤0.01% 240
2022
Q2 		$7K Hold
2,270
– – ﹤0.01% 246
2022
Q1 		$9K Hold
2,270
– – ﹤0.01% 266
2021
Q4 		$21K Sell
2,270
-200
-8% -$2.66K 0.01% 260
2021
Q3 		$41K Hold
2,470
– – 0.01% 249
2021
Q2 		$68K Buy
2,470
+200
+9% +$5.27K 0.02% 256
2021
Q1 		$50K Buy
+2,270
New +$51.9K 0.02% 244

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WealthTrust Axiom's MRKR Position: Q1 2023 in Review

WealthTrust Axiom sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 2,270 shares — an estimated $6.04K sold.

WealthTrust Axiom first reported a position in MRKR in Q1 2021 and held it in 8 quarters. The position peaked at $68K in Q2 2021. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • WealthTrust Axiom reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • WealthTrust Axiom sold 2,270 Marker Therapeutics shares in Q1 2023, an estimated $6.04K.
  • WealthTrust Axiom first reported a position in Marker Therapeutics in Q1 2021 and held it in 8 quarters.
  • WealthTrust Axiom's Marker Therapeutics position peaked at $68K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on WealthTrust Axiom's 13F filing for Q1 2023, filed 3 May 2023.